Development of multi-peptide tumor vaccine for renal cell carcinoma

• Project/Area Number: 25293336
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Kinki University
• Principal Investigator: UEMURA Hirotsugu 近畿大学, 医学部, 教授 (90213397)
• Co-Investigator(Kenkyū-buntansha): DEVELASCO Marco 近畿大学, 医学部, 助教 (20449838) ; MINAMI Takafumi 近畿大学, 医学部, 講師 (70340809) ; HARADA Mamoru 島根大学, 医学部, 教授 (50260716) ; YOSHIMURA Kazuhiro 近畿大学, 医学部, 教授 (20283757)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Project Status: Completed (Fiscal Year 2015)
• Budget Amount: ¥18,070,000 (Direct Cost: ¥13,900,000、Indirect Cost: ¥4,170,000); Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2014: ¥7,800,000 (Direct Cost: ¥6,000,000、Indirect Cost: ¥1,800,000); Fiscal Year 2013: ¥9,100,000 (Direct Cost: ¥7,000,000、Indirect Cost: ¥2,100,000)
• Keywords: 腎細胞癌 / 癌ワクチン / ペプチドワクチン / 免疫療法 / 腎細胞がん / HLA-A24 / 癌ワクチン療法 / EPOR / HIF-1 / PDL-1

Outline of Final Research Achievements

We have been working on the development of new MHC-class-I restricted peptide vaccines for five independent therapeutic targets and have identified a significant candidate EPOR, PDL1 and HIF1. We made the application of patents for EPOR and PDL1 peptide vaccine and are preparing the application for HIF1. Together with CA9 and VEGFR1 previously developed peptide vaccines, we established multi-peptide vaccination system using these five peptide vaccines.

Research Products

• [Journal Article] Identification of programmed death ligand 1-derived peptides capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma (2015)
  • Author(s): Minami T., Minami T., Shimizu N., Yamamoto Y., De Velasco MA., Nozawa M., Yoshimura K., Harashima N., Harada M., Uemura H.
  • Journal Title: Journal of Immunotherapy Volume: 38 (7) Issue: 7 Pages: 285-291
  • DOI: 10.1097/cji.0000000000000090
  • Peer Reviewed
• [Journal Article] New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype alleles (2015)
  • Author(s): Minami T, Minami T, Shimizu N, Yamamoto Y, De Velasco M A, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H.
  • Journal Title: International Immunopharmacology Volume: 26 Issue: 1 Pages: 133-138
  • DOI: 10.1016/j.intimp.2015.03.023
  • Peer Reviewed / Open Access
• [Journal Article] Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24(+) patients with renal cell carcinoma. (2014)
  • Author(s): Minami T, Minami T, Shimizu N, Yamamoto Y, De Velasco M, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H.
  • Journal Title: Int Immunopharmacol. Volume: 20 Pages: 59-65
  • Peer Reviewed
• [Journal Article] Transfection of poly(I:C) can induce ROS-triggered apoptosis and IFN--mediated growth arrest in human renal cell carcinoma cells via innate adjuvant receptors and the 2-5A system (2014)
  • Author(s): Harashima N, Minami T, Uemura H, Harada M
  • Journal Title: Molecular Cancer Volume: 13 Issue: 1 Pages: 217-217
  • DOI: 10.1186/1476-4598-13-217
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Journal Article] Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma. (2014)
  • Author(s): Minami T, Minami T, Shimizu N, Yamamoto Y, De Velasco M, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H
  • Journal Title: Int Immunopharmacol. Volume: 20 Pages: 59-65
  • Peer Reviewed
• [Journal Article] Role of vaccine therapy for renal cell carcinoma in the era of targeted therapy. (2013)
  • Author(s): Yoshimura K, Uemura H. Yoshimura K, Uemura H.
  • Journal Title: Int J Urol. Volume: - Issue: 8 Pages: 1-10
  • DOI: 10.1111/iju.12147
  • NAID: 10031190532
  • Peer Reviewed
• [Journal Article] Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma. (2013)
  • Author(s): Yoshimura K, Minami T, Nozawa M, Uemura H.
  • Journal Title: Br J Cancer. Volume: 108 Issue: 6 Pages: 1260-1266
  • DOI: 10.1038/bjc.2013.90
  • Peer Reviewed
• [Presentation] 去勢抵抗性前立腺癌に対する免疫療法 (2015)
  • Author(s): 吉村一宏、植村天受 ほか
  • Organizer: 第65回 日本泌尿器科学会中部総会
  • Place of Presentation: 長良川国際会議場、岐阜都ホテル
  • Year and Date: 2015-10-23
• [Patent(Industrial Property Rights)] 細胞性免疫に認識されるペプチド、及びそれを利用した医薬薬剤 (2014)
  • Inventor(s): 植村天受
  • Industrial Property Rights Holder: 植村天受
  • Industrial Property Rights Type: 特許
  • Filing Date: 2014-09-17
• [Patent(Industrial Property Rights)] 腎細胞がんの予防又は治療に好適なペプチド、核酸分子、及びベクター、並びにそられの利用 (2014)
  • Inventor(s): 植村天受
  • Industrial Property Rights Holder: 植村天受
  • Industrial Property Rights Type: 特許
  • Industrial Property Number: 2014-007671
  • Filing Date: 2014-01-20